European Commission has launched a formal antitrust investigation into Sanofi for allegedly running a misleading campaign that disparages competitor CSL Seqirus’s Fluad flu vaccine, claiming it is inferior to Sanofi’s Efluelda. The probe concerns communications aimed at healthcare professionals in Germany and France, where Sanofi holds a dominant market position. The Commission cites misleading statements about Fluad’s evidence base, national vaccination recommendations, and unresolved scientific objections. If found unlawful, the conduct could breach Article 102 of the Treaty on the Functioning of the European Union, which prohibits abuse of a dominant position. The investigation is open and does not pre‑judge the outcome. Sanofi can submit commitments to address the Commission’s concerns under Regulation 1/2003. The case is registered as AT.40998 on the Commission’s competition website.
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.